Literature DB >> 30931525

Inactivation of endothelial adenosine A2A receptors protects mice from cerebral ischaemia-induced brain injury.

Yaqi Zhou1,2, Xianqiu Zeng1,2, Ge Li3, Qiuhua Yang1,2, Jiean Xu1,2, Min Zhang1, Xiaoxiao Mao1,2, Yapeng Cao1,2, Lina Wang1, Yiming Xu2,4, Yong Wang2,5, Yu Zhang3, Zhengshuang Xu1,6, Chaodong Wu7, Jiang-Fan Chen8, Md Nasrul Hoda9, Zhiping Liu1,2, Mei Hong1, Yuqing Huo2.   

Abstract

BACKGROUND AND
PURPOSE: Inactivation of the gene for adenosine A2A receptors (ADORA2A for humans and Adora2a for rodents) protects against brain injury in experimental stroke. However, the cell-specific pathogenic effects of A2A receptors in thromboembolic stroke and the underlying mechanisms remain undefined. Here, we tested the hypothesis that inhibition of endothelial A2A receptors after thromboembolic stroke improves post-stroke outcomes via down-regulation of inflammation. EXPERIMENTAL APPROACH: Thromboembolic stroke was induced by embolic middle cerebral artery occlusion in mice. Post-stroke outcomes were determined with neurological deficit scoring, infarct volume, inflammatory marker expression, brain leukocyte infiltration, blood-brain barrier (BBB) leakage, and oedema assessment. Anti-inflammatory effects of silencing the gene for A2A receptors or pharmacological antagonism of these receptors were assessed in vitro. KEY
RESULTS: Thromboembolic stroke induced Adora2a expression in the brain. Mice globally deficient in Adora2a (Adora2a-/- ) were resistant to stroke injury. Mice specifically deficient in endothelial Adora2a (Adora2aΔVEC ) showed reduced leukocyte infiltration, BBB leakage, and oedema after stroke, along with attenuated downstream proinflammatory markers, both in vivo and in vitro. The A2A receptor antagonist, KW 6002, also reduced brain injury and inflammation after stroke. Inactivation of ADORA2A inhibited endothelial inflammation via suppression of the NLRP3 inflammasome, down-regulating cleaved caspase 1 and IL-1β expression. CONCLUSIONS AND IMPLICATIONS: Specific inactivation of endothelial A2A receptors mitigated ischaemic brain injury and improved post-stroke outcomes, at least partly, through anti-inflammatory effects via blockade of NLRP3 inflammasome activity. Our findings may open new approaches to vascular protection after ischaemic stroke.
© 2019 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30931525      PMCID: PMC6555863          DOI: 10.1111/bph.14673

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  The inflammatory response in stroke.

Authors:  Qing Wang; Xian Nan Tang; Midori A Yenari
Journal:  J Neuroimmunol       Date:  2006-12-26       Impact factor: 3.478

3.  Stroke.

Authors:  Brian Owens
Journal:  Nature       Date:  2014-06-26       Impact factor: 49.962

4.  Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

Authors:  J F Chen; K Xu; J P Petzer; R Staal; Y H Xu; M Beilstein; P K Sonsalla; K Castagnoli; N Castagnoli; M A Schwarzschild
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

Review 5.  Pharmacology of adenosine A2A receptors and therapeutic applications.

Authors:  Bertil B Fredholm; Rodrigo A Cunha; Per Svenningsson
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

Review 6.  Can restoring incomplete microcirculatory reperfusion improve stroke outcome after thrombolysis?

Authors:  Turgay Dalkara; Ethem Murat Arsava
Journal:  J Cereb Blood Flow Metab       Date:  2012-10-10       Impact factor: 6.200

Review 7.  Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation.

Authors:  Jiang-Fan Chen; Patricia K Sonsalla; Felicita Pedata; Alessia Melani; Maria Rosaria Domenici; Patrizia Popoli; Jonathan Geiger; Luísa V Lopes; Alexandre de Mendonça
Journal:  Prog Neurobiol       Date:  2007-09-29       Impact factor: 11.685

8.  Tumor necrosis factor-alpha expression in ischemic neurons.

Authors:  T Liu; R K Clark; P C McDonnell; P R Young; R F White; F C Barone; G Z Feuerstein
Journal:  Stroke       Date:  1994-07       Impact factor: 7.914

9.  Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia.

Authors:  G Yang; P H Chan; J Chen; E Carlson; S F Chen; P Weinstein; C J Epstein; H Kamii
Journal:  Stroke       Date:  1994-01       Impact factor: 7.914

10.  Sex-independent neuroprotection with minocycline after experimental thromboembolic stroke.

Authors:  Md Nasrul Hoda; Weiguo Li; Ajmal Ahmad; Safia Ogbi; Marina A Zemskova; Maribeth H Johnson; Adviye Ergul; William D Hill; David C Hess; Irina Y Sazonova
Journal:  Exp Transl Stroke Med       Date:  2011-12-16
View more
  14 in total

1.  Inactivation of endothelial adenosine A2A receptors protects mice from cerebral ischaemia-induced brain injury.

Authors:  Yaqi Zhou; Xianqiu Zeng; Ge Li; Qiuhua Yang; Jiean Xu; Min Zhang; Xiaoxiao Mao; Yapeng Cao; Lina Wang; Yiming Xu; Yong Wang; Yu Zhang; Zhengshuang Xu; Chaodong Wu; Jiang-Fan Chen; Md Nasrul Hoda; Zhiping Liu; Mei Hong; Yuqing Huo
Journal:  Br J Pharmacol       Date:  2019-05-21       Impact factor: 8.739

2.  Pursuing the Molecular Nexus Connecting Diabetes and the Associated Cognitive Impairments.

Authors:  Daniel J Torres; Naghum Alfulaij; Alexandru R Sasuclark; Lígia M Watanabe; Herena Y Ha
Journal:  J Neurosci       Date:  2019-10-30       Impact factor: 6.167

3.  Adenosine A2A receptor controls the gateway of the choroid plexus.

Authors:  Mengqian Ye; Mengru Wang; Yijia Feng; Huiping Shang; Yuwen Yang; Lanxin Hu; Muran Wang; Serhii Vakal; Xiangxiang Lin; Jiangfan Chen; Wu Zheng
Journal:  Purinergic Signal       Date:  2022-02-15       Impact factor: 3.765

4.  Potential Treat-to-Target Approach for Methamphetamine Use Disorder: A Pilot Study of Adenosine 2A Receptor Antagonist With Positron Emission Tomography.

Authors:  Kyoji Okita; Toshihiko Matsumoto; Daisuke Funada; Maki Murakami; Koichi Kato; Yoko Shigemoto; Noriko Sato; Hiroshi Matsuda
Journal:  Front Pharmacol       Date:  2022-05-11       Impact factor: 5.988

Review 5.  Caffeine and Its Neuroprotective Role in Ischemic Events: A Mechanism Dependent on Adenosine Receptors.

Authors:  R Brito; K C Calaza; D Pereira-Figueiredo; A A Nascimento; M C Cunha-Rodrigues
Journal:  Cell Mol Neurobiol       Date:  2021-03-17       Impact factor: 5.046

Review 6.  NLRP3 inflammasome in endothelial dysfunction.

Authors:  Baochen Bai; Yanyan Yang; Qi Wang; Min Li; Chao Tian; Yan Liu; Lynn Htet Htet Aung; Pei-Feng Li; Tao Yu; Xian-Ming Chu
Journal:  Cell Death Dis       Date:  2020-09-18       Impact factor: 8.469

Review 7.  Purinergic Regulation of Endothelial Barrier Function.

Authors:  Muhammad Aslam; Dursun Gündüz; Christian Troidl; Jacqueline Heger; Christian W Hamm; Rainer Schulz
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

8.  Adenosine A2A receptor agonist polydeoxyribonucleotide ameliorates short-term memory impairment by suppressing cerebral ischemia-induced inflammation via MAPK pathway.

Authors:  Il-Gyu Ko; Jun-Jang Jin; Lakkyong Hwang; Sang-Hoon Kim; Chang-Ju Kim; Jung Won Jeon; Jun-Young Chung; Jin Hee Han
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

Review 9.  Purinergic Signaling in the Regulation of Gout Flare and Resolution.

Authors:  Xiaoling Li; Jie Gao; Jinhui Tao
Journal:  Front Immunol       Date:  2021-12-01       Impact factor: 7.561

Review 10.  G-Protein-Coupled Receptors and Ischemic Stroke: a Focus on Molecular Function and Therapeutic Potential.

Authors:  Zeinab Vahidinia; Mohammad Taghi Joghataei; Cordian Beyer; Mohammad Karimian; Abolfazl Azami Tameh
Journal:  Mol Neurobiol       Date:  2021-06-12       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.